Tiziana Life Sciences Ltd
NASDAQ:TLSABiotechnology
+$0.03 today
- Market cap
- $103.50M
- Beta
- 0.42
- P/E (TTM)
- -4.0
- EPS (TTM)
- -$0.19
Volume 1.28M
Average 0.21M
TLSA Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Tiziana Life Sciences LtdNASDAQ: TLSA
Selling, General & Admin · Q4 FY2025 · quarter ended Dec 2025
Selling, general & admin declines year over year
Q4 FY2025 selling, general & admin of $5.15M fell 20.6% year over year. Over 3 fiscal years it compounded at +31.3% a year.
Context
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +4.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterDec 2025
- $5.15M— QoQ
- Last fiscal yearDec 2025
- $10.77M+4.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -20.6% | — | — |
| 1 year | +4.7% | -100.0% | -104.7 pp |
| 3-year CAGR | +31.3% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 10.77M USD
- Year-over-year change
- +4.7%
- 4-year CAGR
- +74.8%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 10.77M | +4.7% |
| FY2024 | 2024-12-31 | 10.28M | +24.6% |
| FY2023 | 2023-12-31 | 8.26M | +73.3% |
| FY2022 | 2022-12-31 | 4.76M | +313.0% |
| FY2021 | 2021-12-31 | 1.15M | — |
Selling, General & Admin vs competitors
How TLSA compares with its peers on the latest reported figures
- TLSA's FY2025 selling, general & admin of $10.77M is the 7th highest of the 9 companies compared; the peer median is $29.13M.
- Its year-over-year change of +4.7% is the 4th highest of 9, against a peer median of -30.3%.
- Over three fiscal years its annual growth of +31.3% compares with a peer median of +2.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $6.7B | +73001.9% | +33.2% | 84342.9% | |
| LTM Mar 2026 | $39.91M | -32.7% | +5.7% | — | |
| LTM Mar 2026 | $38.15M | -27.9% | -12.7% | 24.3% | |
| LTM Mar 2026 | $34.97M | -57.3% | -11.6% | — | |
WHWKWhitehawk Therapeutics Inc | LTM Mar 2026 | $23.29M | -40.2% | -9.5% | — |
| LTM Mar 2026 | $15.81M | +34.6% | +50.4% | — | |
| FY2025 | $10.77M | +4.7% | +31.3% | — | |
EXOZeXoZymes, Inc. | LTM Mar 2026 | $5.71M | +24.9% | +91.9% | — |
| FY2025 | $4.93M | -33.8% | +0.0% | — | |
| Peer median (excluding TLSA) | $29.13M | -30.3% | +2.9% | 42183.6% | |
Competitors are the stored peer set for TLSA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 234K |
| Gross Profit | 0 | 0 | 0 | 0 | (234K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 17.82M | 15.92M | 10.25M | 5.23M | 10.28M |
| Selling, General & Admin | 1.15M | 4.76M | 8.26M | 10.28M | 10.77M |
| Operating Expenses | 36.93M | 17.93M | 22.73M | 15.79M | 21.05M |
| Depreciation & Amortization | 190.2K | 62.68K | 121.34K | 124K | 234K |
| EBITDA | (35.53M) | (18.85M) | (21.66M) | (16.62M) | (21.05M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (36.93M) | (17.93M) | (22.73M) | (15.79M) | (21.28M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 1.46M | 814K | 19K |
| Interest Expense | 237.41K | 8.6K | 12.64K | 6K | 18K |
| Other Income / Expenses | 967.18K | (996.78K) | 937.89K | (952K) | 2.85M |
| Income Before Tax | (35.96M) | (18.92M) | (21.79M) | (16.75M) | (18.43M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | (4.37M) | 0 | 567.54K | (4.88M) | 0 |
| Net Income | (31.59M) | (18.92M) | (22.36M) | (11.86M) | (18.43M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.64) | (0.36) | (0.42) | (0.22) | (0.32) |
| EPS (Diluted) | (0.64) | (0.36) | (0.42) | (0.22) | (0.32) |
| Weighted Avg Shares | 48.97M | 50.76M | 50.76M | 53.34M | 59.14M |
| Weighted Avg Shares (Diluted) | 48.97M | 50.76M | 50.76M | 53.34M | 59.14M |
Tiziana Life Sciences Ltd
NASDAQ:TLSA
Intrinsic Alpha fair value
Locked
Current Price
$0.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.